Navigation Links
TPI Discusses Non-Cash Non-Operational Financial Impact from Warrants
Date:6/17/2011

cided to amend the Company's Form 10-Qs for the quarters ended September 30, 2010, December 31, 2010 and March 31, 2011 reporting periods including the comparative prior year period in these filings to reflect the non-cash, non-operational financial impact from the reclassification of the Warrants. The Company will also make corresponding revisions to its financial statements for the fiscal year ended June 30, 2010 in the Form 10-K for the fiscal year ended June 30, 2011.

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharm
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. VHGI Discusses Recent Addition to the Regulation SHO Threshold Security Listing
3. Robotic Surgery Expert Dr. David B. Samadi, MD Discusses New Evidence That Proves The Low Complication Rates of Robotic Prostatectomy
4. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
5. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
6. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
7. Robotic Surgery Expert Dr. David Samadi, MD Discusses FDA Warnings on the Effect of GnRH Agonists
8. New York Robotic Surgery Expert Dr. David Samadi, MD Discusses New Findings that Hormone Therapy May Increase Risk of Developing Colorectal Cancer
9. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Staging and Prostate Cancer Recurrence Study
10. Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment
11. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Inferior Vena Cava (IVC) Filters - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... projected to reach US$435 million by 2016. The ... (2015) of the global value while Europe ...
(Date:12/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... added to the NASDAQ Biotechnology Index (NBI). The ... effective upon market open on December 22, 2014. ... to track the performance of a set of ... or pharmaceutical according to the Industry Classification Benchmark. ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 2014 Emergo Group, Inc., a medical ... in North and South America, Europe, the Middle East, ... participants for its 2015 Medical Device Industry Survey. Each ... upcoming business and market trends as well as regulatory ... targets areas including:, , Overall prospects ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Schizophrenia is one of the most disabling diseases,(1) ... of the disease place enormous burdens on patients, ... the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment ... reduce rates of rehospitalization among patients with schizophrenia. ...
... Calif., May 19 Apieron, Inc. ( www.apieron.com ... the appointment of Steve Bubrick as Vice President, Sales ... Both appointments are effective immediately. Mr. Bubrick has more ... the consumer medical device industry, mainly in diabetes management. ...
... Encision Inc. (OTC Bulletin Board: ECIA), a medical ... as a standard of care in minimally-invasive surgery, reported ... year ended March 31, 2009.Net sales for the fourth ... totaled $3.1 million, representing a 3% decrease over net ...
... STOCKHOLDERSADVOCAT BOARD NEEDS TO EXPLORE THE SALE OR MERGER ... Fund, Ltd. ("Bristol") announced today that it has sent ... "Company") (Nasdaq: AVCA ) urging stockholders to ... Paul Kessler and Richard McKilligan, at the Company,s 2009 ...
... athlete,s foot sufferers and parents.KENILWORTH, N.J., May 19 ... SGP ) today announced the arrival ... treatment of athlete,s foot. TINACTIN CHILL is available ... spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 )To view the ...
... Mark Best Programs in Sustainable Healthcare CHICAGO, ... only membership association devoted to environmentally responsible ... Award winners. These competitive awards are ... for outstanding programs to reduce the facility,s ...
Cached Medicine News:Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 2Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 3Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 4Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 5Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 6Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 7Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 8Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 9Health News:New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 10Health News:Apieron Strengthens Senior Leadership With Commercial, Financial Appointments 2Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 2Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 3Health News:Encision Reports Fourth Quarter and Fiscal Year 2009 Results 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 3Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 5Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 6Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 7Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 8Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 9Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 3Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 4Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 5Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 6Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 7Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 8
Stainless Steel. Sterile. 2 pieces/box...
... attributes of the IMMULITE 2000, the IMMULITE ... Logic Driven Incubation (LDI). Using a newly ... be formatted for optimal performance with the ... assays, such as Siemens Diagnostics' cardiac biomarkers ...
... The SMS is a robotic sample feeder that ... systems via a robotic arm and the SMS ... 200 tubes and compatibility with clinical chemistry system ... make the SMS a practical and affordable solution ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
Medicine Products: